Quetiapine

From Wikipedia, the free encyclopedia

Quetiapine
Systematic (IUPAC) name
2-(2-(4-dibenzo[b,f][1,4]thiazepine- 11-yl- 1-piperazinyl)ethoxy)ethanol
Identifiers
CAS number	111974-69-7
ATC code	N05AH04
PubChem	5002
DrugBank	APRD00675
ChemSpider	4827
Chemical data
Formula	C21H25N3O2S
Mol. mass	383.5099 g/mol
SMILES	eMolecules & PubChem
Pharmacokinetic data
Bioavailability	9%
Metabolism	Hepatic
Half life	6 hours
Excretion	Renal
Therapeutic considerations
Pregnancy cat.	C(US)
Legal status	℞-only(US)
Routes	Oral

Quetiapine (pronounced /kwɨˈtaɪ.əpiːn/ kwi-TYE-ə-peen), marketed by AstraZeneca as Seroquel and by Orion Pharma as Ketipinor, is an atypical antipsychotic used in the management of schizophrenia and bipolar I disorder, and used off-label for a variety of other purposes, including insomnia and anxiety disorders.

Annual sales are approx. $4.7bn. The patent expires in 2011, however in Canada it has already expired. Several pharmaceutical companies are now making generic versions of Quetiapine.

[edit] Uses

Quetiapine (Seroquel) 25 mg tablets, next to US one-cent coin for comparison.

Quetiapine is indicated for the treatment of schizophrenia, depressive episodes associated with bipolar disorder, acute manic episodes associated with bipolar I disorder (as either monotherapy or adjunct therapy to lithium or divalproex), and maintenance treatment of bipolar I disorder (as adjunct therapy to lithium or divalproex). Quetiapine received its initial indication from the U.S. Food and Drug Administration for treatment of schizophrenia in 1997. In 2004, it received its second indication for the treatment of mania-associated bipolar disorder.^[1] It is sometimes used off-label, often as an augmentation agent, to treat such conditions as obsessive-compulsive disorder, post-traumatic stress disorder, restless legs syndrome, autism, alcoholism,^[2] Tourette syndrome,^[3] and has been used by physicians as a sedative for those with sleep disorders or anxiety disorders.^[4]

In 2005, Quetiapine and other antipsychotics were shown by the New England Journal of Medicine to be no more effective than perphenazine (Trilafon), a typical antipsychotic, for the treatment of schizophrenia. However, the subsequent CATIE trial, funded by AstraZeneca and other major pharmaceutical manufacturers,^[5] contradicted the 2005 study in certain instances.

A 2005 British Medical Journal report showed that Quetiapine was ineffective in reducing agitation among Alzheimer's patients, whose consumption of the drug then constituted 29% of sales; in fact, Quetiapine was found to make cognitive functioning worse in elderly patients with dementia.^[6]

Use of Quetiapine to minimize the symptoms of opioid withdrawal has been studied.^[7]

Phase III trials are being conducted to prove Quetiapine's efficacy in treating generalized anxiety disorder and major depressive disorder as of January 2007. The company expects to file a New Drug Application for treating generalized anxiety disorder in the second half of 2007 and for major depressive disorder in 2008.^[8]

AstraZeneca's patent for Seroquel expires in the United States in September 2011, which will allow other companies to manufacture and market quetiapine.

[edit] Pharmacology

The antipsychotic effect of quetiapine is thought by some to be mediated through antagonist activity at dopamine and serotonin receptors. Specifically the D₁ and D₂ dopamine receptor, the alpha-1 and alpha-2 adrenergic receptor, and 5-HT_1A and 5-HT₂ serotonin receptor subtypes are antagonized.^[9] Serial PET scans evaluating the D₂ receptor occupancy of quetiapine have demonstrated that quetiapine very rapidly disassociates from the D₂ receptor.^[10] Theoretically, this allows for normal physiological surges of dopamine to elicit their normal effects in areas such as the nigrostriatal and tuberoinfundibular pathways, thus minimizing the risk of side effects such as pseudo-parkinsonism as well as elevations in prolactin.^{[citation needed]}

Quetiapine also has an antagonistic effect on the histamine H₁ receptor. This is thought to be responsible for the sedative effect of the drug.^[11]

[edit] Forms

Quetiapine is available under the brand name Seroquel. It was originally available in 25 mg, 50 mg, 100 mg, 200 mg, and 300 mg tablets. 400 mg tablets have since been introduced to increase dosing flexibility.

[edit] Sustained-release quetiapine (Seroquel XR)

AstraZeneca has submitted a New Drug Application for a sustained-release version of quetiapine in the United States, Canada, and the European Union in the second half of 2006 for treatment of schizophrenia.^[12][13] AstraZeneca will retain the exclusive right to market sustained release quetiapine until 2017.

On May 18, 2007, AstraZeneca announced that the U.S. Food and Drug Administration has approved Seroquel XR for acute treatment of schizophrenia.^[14] During its 2007 Q2 earnings conference, AstraZeneca announced plans to launch Seroquel XR in the U.S. during August 2007.^[15] However, Seroquel XR has only become available in U.S. pharmacies after the FDA approved Seroquel XR for use as maintenance treatment for schizophrenia, in addition to acute treatment of the illness, on November 16, 2007.^[16] The company has not provided a reason for the delay of Seroquel XR's launch.

Health Canada approved sale of Seroquel XR on September 27, 2007.^[17]

Seroquel XR was approved for the treatment of bipolar depression and bipolar mania by the U.S. Food and Drug Administration (FDA) in early October, 2008. According to AstraZeneca, Seroquel XR is "the first medication approved by the FDA for the once-daily acute treatment of both depressive and manic episodes associated with bipolar."

On December 1, 2008, Biovail announced that the U.S. FDA has accepted the company's Abbreviated New Drug Application (ANDA) to market its own version of sustained-release quetiapine.^[18] Biovail's sustained-release tablets will compete with AstraZeneca's Seroquel XR.

On December 24, 2008, AstraZeneca notified its shareholders that the U.S. FDA has asked for additional information on the company's application to expand the use of sustained-release quetiapine for treatment of depression.^[19]

[edit] Side effects

Quetiapine has multiple side effects, some of them common, a few of them serious and life-threatening.

The most common side effect of quetiapine is sedation,^[20] and it is marketed as one of the most sedating of all antipsychotics, albeit those efficacy claims are contested.^[21] Beginning users may feel extremely tired and 'out of it' for the first few days, sometimes longer. Quetiapine's newest indication, for bipolar depression, usually specifically calls for the entire dose to be taken before bedtime due to its sedative effects. Although quetiapine is approved by the FDA only for the treatment of schizophrenia and bipolar disorder, it is frequently prescribed off-label for other purposes, including insomnia and the treatment of anxiety disorders. The sedative effects may disappear after some time on the drug, or with a change of dosage, and with possibly different, non-sedative side effects emerging.

Common side effects include weight gain^[21], constipation, headache and dry mouth. Six to seven percent of patients may experience tachycardia. Less common side effects (less than 1% of patients) include abnormal liver tests, dizziness, upset stomach, substantial weight gain, a stuffy nose, akathisia and increased paranoia.

There is a risk of development of tardive dyskinesia, an incurable neurological disorder, with any prolonged use of quetiapine and some other neuroleptic drugs. However, quetiapine is believed to cause tardive dyskinesia somewhat less often than typical antipsychotics based on the data sources which point to placebo-level incidence of extrapyramidal side effects.^[22][23]

The rare, but life-threatening, neuroleptic malignant syndrome may also result from quetiapine use.

Weight gain can be a problem for some patients using quetiapine, by causing the patient's appetite to persist even after meals. However, this effect may occur to a lesser degree compared to some other atypical antipsychotics such as olanzapine or clozapine.

As with other atypical antipsychotics, there is evidence suggesting a link to the development of diabetes and blood sugar disorders, however this remains controversial due to disparities between the results of studies. In the United States, two separate lawsuits—over claims that quetiapine use has led to diabetes—have been filed in federal court.^[24] A Delaware state court is scheduled to hear a trial alleging a link between Seroquel and diabetes in June 2009.^[25] The Delaware case will be the first case to go to trial on allegations that AstraZeneca withheld information about a link between Seroquel and diabetes.^[25]

Studies conducted on beagles have resulted in the formation of cataracts—while there are reports of cataracts occurring in humans, controlled studies including thousands of patients have not demonstrated a clear causal association between quetiapine therapy and this side effect. (Reference needed to April 2006 results of CATIE study.) However, the Seroquel website^[26] still recommends users have eye examinations every six months.

As with some other antipsychotics, quetiapine may lower the seizure threshold, and should be taken with care in combination with drugs such as bupropion.

[edit] Recreational use

Quetiapine is not currently classified as a controlled substance. Reports of quetiapine abuse have emerged in the medical literature, however. While the drug is usually abused through the crushing and snorting of tablets (insufflation), there have also been reports of intravenous abuse and intravenous co-administration with cocaine.^[27] This is commonly referred to as a Rosemary's Dolly. A 2004 report recorded a 30% rate of inmate use in the Los Angeles County Jail, where the drug was obtained by inmates faking schizophrenic symptoms and resold under the street name "quell".^[28] Also known as "Susie-Q", the drug may be more commonly abused in prisons due to its capacity to be regularly prescribed as a sedative and the unavailability in prison of more commonly abused substances. A letter to the editor which appeared in the January 2007 American Journal of Psychiatry has proposed a “need for additional studies to explore the addiction-potential of quetiapine”. The letter reports that its authors are physicians who work in the Ohio correctional system. They report that “prisoners ... have threatened legal action and even suicide when presented with discontinuation of quetiapine” and that they have “not seen similar drug-seeking behavior with other second-generation antipsychotics of comparable efficacy”.^[29]

Along with benzodiazepines, atypical antipsychotics have sometimes been used to "come down" off cocaine or amphetamines. When used in this manner the slang term "downer" is often applied.

[edit] References

[edit] External links

• MedlinePlus summary
• NAMI summary
• Internet Drug List summary
• Compound #1802: Quetiapine ChemBank
• Intranasal Quetiapine Abuse